Natural Medicine Advisory Bulletin 10.1: Legislative Update
Reading Time: 2 minutes On April 4, 2024, the Colorado General Assembly introduced Senate Bill 24-198, the first legislative
Reading Time: 2 minutes On April 4, 2024, the Colorado General Assembly introduced Senate Bill 24-198, the first legislative
Reading Time: < 1 minute Last month, psychedelic drug developer MindMed scored an FDA breakthrough therapy designation for its LSD-D-tartrate candidate (MM120)
Reading Time: 3 minutes Josh Hardman, Psychedelic Alpha: The Bill references “any form of psilocybin or methylenedioxymethamphetamine that is
Reading Time: < 1 minute In this issue of the Psychedelic Patent Analysis, we look at IP and exclusivity in MDMA
Reading Time: 2 minutes Pre-clinical/Basic SciencesTo start off the conference, Dr. Kevin Murnane, Associate Professor at Louisiana State University
Reading Time: < 1 minute This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead
Reading Time: 4 minutes Department of Regulatory Agencies Stakeholder Engagement Meeting: March 8th, 2024On Friday, March 8th, the Department
Reading Time: < 1 minute Today, psychedelic drug developer Cybin announced that it has received breakthrough therapy designation for CYB003,
Reading Time: 8 minutes Hardman: I want to pick up on something that you started talking about: the corporatisation
Reading Time: < 1 minute Featured content in this Issue: Fluence and UPRA Team Up to Bring Psychedelic Therapy Training